AgomAb Therapeutics
Signal active
Organization
Contact Information
Overview
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
About
Industries
Biotechnology, Health Care, Therapeutics
Founded
2017
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
AgomAb Therapeutics headquartered in Europe, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $11.4B in funding across 48 round(s). With a team of 11-50 employees, AgomAb Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - AgomAb Therapeutics, raised $100.8M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
12
Lead Investors
0
Total Funding Amount
$237.0M
Details
4
AgomAb Therapeutics has raised a total of $237.0M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 74.0M | ||
| 2019 | Early Stage Venture | 23.6M | ||
| 2022 | Early Stage Venture | 38.5M | ||
| 2023 | Late Stage Venture | 100.8M |
Investors
AgomAb Therapeutics is funded by 48 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Redmile Group | - | FUNDING ROUND - Redmile Group | 100.8M |
| Andera Partners | - | FUNDING ROUND - Andera Partners | 100.8M |
| Walleye Capital | - | FUNDING ROUND - Walleye Capital | 100.8M |
| AgomAb Therapeutics | - | FUNDING ROUND - AgomAb Therapeutics | 100.8M |
Recent Activity
There is no recent news or activity for this profile.